Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 2004

View Archived Issues

Comparison of the gastric safety of valdecoxib and naproxen in elderly volunteers

Three series of COX-2 inhibitors designed at Almirall Prodesfarma

BMS scientists present two novel series of factor VIIa inhibitors

Therapeutic benefits of omalizumab in allergy conjunctivitis

New pharmacokinetic data for ramelteon presented at the ACCP meeting

Two novel series of chemokine CCR2 antagonists identified at BMS

Novel anti-HCV agents targeting NS3-NS4A protease claimed by Enanta

Three series of GSK-3beta inhibitors in early development at Sanofi-Synthelabo

Japanese team describes flavonoids acting at aldose reductase, AGE formation and free radicals

Selective topoisomerase I poison for cancer therapy

Combination treatment with Abbott PARP inhibitor and doxorubicin increases life span

Analogues of antiangiogenic agent NM-3 show enhanced antiproliferative activity in vivo

Human monoclonal antibody promising against SARS in vivo

Provensis continues work to lift Varisolve clinical hold

SkyePharma and Merck KGaA revise agreement for phase III project

European submission seeks approval of Dacogen for MDS

Positive safety data from phase I/II study of HuMax-EGFr

New phase II study for SDX-101 in CLL commences enrollment

NABTT studies SDX-102 for brain tumors

Medarex receives NIAID grants to develop MDX-1303 for anthrax infection

European approval for Protelos

No cardiovascular issues in long-term studies of Celebrex

Dose-ranging study for premature ejaculation compound LI-301

TACI-Ig cleared to enter phase Ib studies in advanced B-cell malignancies

Phase III trial of Ikomio for ALS fails to show survival benefit

Entecavir submitted for U.S., European marketing approval for hepatitis B

Pro-Pharmaceuticals presents an update on the clinical development of Davanat-1 in cancer

Therapeutic effects of HepeX-B in patients with chronic HBV infection

A clinical trial confirms the antibacterial efficacy of telavancin in cSSTI

Apidra receives European approval

Febuxostat pharmacokinetics, pharmacodynamics and safety studied

Antitumor activity of EXEL-7647 observed in vivo

EXEL-0999 active in solid tumor and leukemia models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...